Delivery Order SPE2DB24D2102-SPE2DB25FJJSS
- Not listed
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (30-count unit dose packaging) with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract is classified as a non-set-aside and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) with a firm fixed price structure. The contract, which is not set-aside, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of September 30, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $13,846.97 on July 28, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count) with a completion deadline of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $13,846.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (unit dose, 30-count packages) on September 11, 2025, with an ultimate completion date of October 2, 2025. This non-set-aside competitive award represents a child delivery order against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December...
- The Defense Logistics Agency awarded a $13,846.97 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packages of 30 units. This is a firm fixed price, non-set-aside contract with an ultimate completion date of September 18, 2025, to be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyndamax 61 mg capsules in unit dose packages of 30 count. This is a firm fixed price delivery order with a ceiling value of $27,693.94 and an ultimate completion date of September 16, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $27,693.94 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Vyndamax 61 mg capsule unit dose packages (30-count). The contract, which is not set-aside and competitively awarded, specifies an ultimate completion date of September 24, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $13,846.97 to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsule unit dose packs (30-count) on August 27, 2025, with an ultimate completion date of September 18, 2025. The contract is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a $13,846.97 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsules (30-count unit dose packaging) on September 8, 2025, with completion targeted for September 29, 2025. This non-set-aside contract was competitively awarded and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $13,846.97 to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsule unit dose packages (30-count) on September 11, 2025, with an ultimate completion date of October 2, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract utilizing the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle...
- SPE2DB24D2102Indefinite Delivery Contract
- SPE2DB24D2102-SPE2DB25FJJSSDelivery Order
The Defense Logistics Agency awarded a $27,693.94 delivery order to AmerisourceBergen Drug Corp for Vyndamax 61 mg capsule unit dose packages (30-count) on September 11, 2025, with an ultimate completion date of October 2, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The vendor, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly for military and veteran healthcare systems. The company's portfolio with the Defense Logistics Agency encompasses a broad range of pharmaceutical products and medical supplies across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. This specific delivery order for Vyndamax—a medication used primarily to treat hereditary transthyretin amyloidosis—exemplifies the company's role in supplying specialized pharmaceutical commodities to support Department of Defense healthcare requirements through DLA's Medical Supply Chain network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.7k | 9/11/25 |